🇺🇸 FDA
Pipeline program

GLPG0634

GLPG0634-CL-211

Phase 2 small_molecule completed

Quick answer

GLPG0634 for Crohn's Disease is a Phase 2 program (small_molecule) at Lakefront Biotherapeutics NV with 1 ClinicalTrials.gov record(s).

Program details

Company
Lakefront Biotherapeutics NV
Indication
Crohn's Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials